This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hims & Hers Stock to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
HIMS' second-quarter 2025 results are likely to benefit from subscriber momentum and digital care tools.
Unlocking Q1 Potential of McKesson (MCK): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of McKesson (MCK) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Why McKesson (MCK) Dipped More Than Broader Market Today
by Zacks Equity Research
McKesson (MCK) reached $693.54 at the closing of the latest trading day, reflecting a -2.99% change compared to its last close.
Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conmed (CNMD) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of +1.77% and +0.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Why Growth Investors Shouldn't Overlook McKesson (MCK)
by Zacks Equity Research
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Are Medical Stocks Lagging McKesson (MCK) This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Cencora (COR) have performed compared to their sector so far this year.
Wall Street Bulls Look Optimistic About McKesson (MCK): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for McKesson (MCK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Strength Seen in ProDex (PDEX): Can Its 8.2% Jump Turn into More Strength?
by Zacks Equity Research
ProDex (PDEX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's Why McKesson (MCK) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Why McKesson (MCK) Dipped More Than Broader Market Today
by Zacks Equity Research
McKesson (MCK) concluded the recent trading session at $724.11, signifying a -1.53% move from its prior day's close.
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is It Worth Investing in McKesson (MCK) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), McKesson (MCK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Here's Why McKesson (MCK) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson (MCK) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
McKesson (MCK) closed at $705.45 in the latest trading session, marking a -3.06% move from the prior day.
These Top 4 Women-Run Company Stocks Are Quietly Beating the Market
by Shrabana Mukherjee
These women-run company stocks offer high growth and stability.